Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-In-Human, Open-Label, Dose-Escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Ascending Intravenous Doses of BITR2101 (Anti-TNFR2) in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Including Cutaneous and Peripheral T Cell Lymphoma

NCT06385522 is registered in ClinicalTrials.gov with Boston Immune Technologies and Therapeutics as lead sponsor.

NCT NCT06385522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06385522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-In-Human, Open-Label, Dose-Escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Ascending Intravenous Doses of BITR2101 (Anti-TNFR2) in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Including Cutaneous and Peripheral T Cell Lymphoma
Lead sponsor
Boston Immune Technologies and Therapeutics
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 31, 2025
Completion date
February 28, 2027
Enrollment
37 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t cell lymphoma, nhl, peripheral t-cell lymphoma